Strategic Partnerships Viralgen thrives on collaboration with biotech groups and has recent and ongoing partnerships with Elaaj Bio, Apertura Gene Therapy, Trogenix, Axovia Therapeutics, and broader collaborations tied to TfR1 CapX programs, indicating a clear opportunity to propose expanded CDMO services and co-development arrangements with compatible gene therapy players.

AAV Manufacturing Focus As a specialized CDMO for recombinant AAV production with GMP-certified facilities in San Sebastian, Viralgen is well-positioned to offer end-to-end services from large-scale manufacturing to fill-finish and QC, making it a strong target for gene therapy programs seeking reliable scalable production.

Therapy Pipeline Viralgen is actively advancing therapies including prion disease programs in collaboration with top research institutions, signaling potential for higher-value, novel indications and the need for dedicated manufacturing support as these programs move toward clinical stages.

Sustainability & Capability Leveraging a robust suspension platform and integration with AskBio technology, Viralgen demonstrates scalable, technically advanced capabilities that appeal to CDMO buyers seeking modern, efficient manufacturing workflows and rapid market readiness.

Commercial Readiness With a revenue range of 10–25 million and a growing customer base through multiple partnerships, Viralgen presents opportunities for expansion in fill-finish and quality control services, as well as potential upsell into broader GMP-compliant manufacturing and analytical testing offerings.